| Biomarker ID | 2003 |
| PMID | 22589488 |
| Year | 2012 |
| Biomarker | Methylation status of BCL11B |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Methylated in systemic Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Systemic recurrence vs. local recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Systemic recurrence (n = 36) versus local recurrence (n = 44) |
| Senstivity | Training:82.6 (61.2–95.0); validation: 75.2 (50.9–91.3) |
| Specificity | Training: 80.5 (63.9–91.8); validation: 60.0 (36.0–80.8) |
| AUC | Training: 0.80; validation: 0.74 |
| Accuracy | NA |
| Level Of Significance | <0.0001 |
| Method Used | Pyrosequencing |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | BCL11B |